Vera Bittner

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

To assess whether a short period of very low LDL-C (<0.39 mmol/L or 15 mg/dL) achieved with a statin plus the PCSK9 inhibitor alirocumab, followed by blinded placebo substitution and continued statin alone, is associated with a legacy effect of lower cardiovascular risk in patients with recent acute coronary syndrome. This is a post hoc analysis of the ODYSSEY OUTCOMES trial. Note: this study has published corrections/errata; readers should check the correction notices for updated information.